SABS SAB Biotherapeutics Inc

Price (delayed)

$3.39

Market cap

$308.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$305.31M

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 48
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 22

SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent ...

Highlights
The EPS has soared by 84% YoY and by 56% QoQ
SAB Biotherapeutics's net income has surged by 66% YoY
SAB Biotherapeutics's revenue has shrunk by 100% YoY
SAB Biotherapeutics's gross profit has shrunk by 100% YoY

Key stats

What are the main financial stats of SABS

SABS stock price

How has the SAB Biotherapeutics stock price performed over time
Intraday
-3.14%
1 week
0%
1 month
-10.32%
1 year
50%
YTD
-9.36%
QTD
-13.08%

Financial performance

How have SAB Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.82M
Net income
-$12.78M
Gross margin
N/A
Net margin
N/A
SAB Biotherapeutics's revenue has shrunk by 100% YoY
SAB Biotherapeutics's gross profit has shrunk by 100% YoY
SABS's operating income has plunged by 72% YoY and by 23% from the previous quarter
SAB Biotherapeutics's net income has surged by 66% YoY

Price vs fundamentals

How does SABS's price correlate with its fundamentals

Growth

What is SAB Biotherapeutics's growth rate over time

Valuation

What is SAB Biotherapeutics stock price valuation
P/E
N/A
P/B
1.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 84% YoY and by 56% QoQ
The P/B is 43% below the 5-year quarterly average of 2.2 but 39% above the last 4 quarters average of 0.9
SAB Biotherapeutics's equity has decreased by 5% QoQ
SAB Biotherapeutics's revenue has shrunk by 100% YoY

Efficiency

How efficient is SAB Biotherapeutics business performance
The ROE has soared by 96% YoY
SAB Biotherapeutics's ROIC has soared by 94% YoY
SABS's ROA has soared by 93% YoY

Dividends

What is SABS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SABS.

Financial health

How did SAB Biotherapeutics financials performed over time
The total liabilities rose by 29% year-on-year and by 10% since the previous quarter
The quick ratio has contracted by 20% from the previous quarter
The company's debt is 98% lower than its equity
SABS's debt to equity has dropped by 96% year-on-year and by 33% since the previous quarter
The company's debt fell by 20% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.